People taking TRIKAFTA reported a significant 20.1-point average increase in CF respiratory symptom score compared with placebo at 4 weeks.

In Trial 1, mean baseline CFQ-R Respiratory Domain score was 68.3 for patients receiving TRIKAFTA and 70.0 for those receiving placebo. CFQ-R Respiratory ...

31 окт. 2019 г. · In proof-of-concept trials that evaluated this therapeutic approach, elexacaftor–tezacaftor–ivacaftor led to improvements in spirometry, patient ...

7 июн. 2024 г. · TRIKAFTA showed sustained improvement in lung function at three years as well as lower rates of lung transplant and death in people with cystic fibrosis.

3 июл. 2021 г. · The studies showed a significant improvement in lung function, and respiratory-related quality of life, and a decrease in pulmonary ...

Trial 3 was a 2-part study: Part A was a pharmacokinetic and safety study, and Part B evaluated safety, tolerability, efficacy, and pharmacokinetics.

31 окт. 2019 г. · Patients received twice daily TRIKAFTA or placebo for 24 weeks. The primary efficacy endpoint was change in lung function as determined by ...

5 февр. 2024 г. · Treatment with the once-daily vanza triple CFTR modulator regimen met all primary and key secondary endpoints in two randomized controlled trials.

Harms Results. Patients With F/MF Genotype (Study 102). The overall percentage of patients who experienced at least 1 AE was 96.0% in the placebo group and ...

At baseline, 36% of participants reported a CFQ-R RD score of at least 80 points, and 4% reported the maximum score of 100. After steady improvement, 85% had ...